Cargando…

External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy

The aim of this study was to externally validate a nomogram for side-specific extraprostatic extension (EPE) of prostate cancer (PCa) at robot-assisted radical prostatectomy (RARP). A prospectively maintained cohort of 1170 consecutive patients with PCa who underwent RARP at two high-volume RARP cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Veerman, Hans, Heymans, Martijn W., van der Poel, Henk G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883192/
https://www.ncbi.nlm.nih.gov/pubmed/35243390
http://dx.doi.org/10.1016/j.euros.2021.12.010
_version_ 1784659871632719872
author Veerman, Hans
Heymans, Martijn W.
van der Poel, Henk G.
author_facet Veerman, Hans
Heymans, Martijn W.
van der Poel, Henk G.
author_sort Veerman, Hans
collection PubMed
description The aim of this study was to externally validate a nomogram for side-specific extraprostatic extension (EPE) of prostate cancer (PCa) at robot-assisted radical prostatectomy (RARP). A prospectively maintained cohort of 1170 consecutive patients with PCa who underwent RARP at two high-volume RARP centres between 2018 and 2021 was retrospectively evaluated. Biopsies and magnetic resonance imaging (MRI) scans were centrally reviewed. The side-specific probability of EPE was calculated for each prostate side using prostate-specific antigen density, ipsilateral highest biopsy Gleason score, and ipsilateral MRI tumour stage. Model discrimination and calibration were analysed using the area under the receiver operating characteristic curve (AUC), calibration in the large, and calibration curves. The rate of side-specific EPE was 30% among 2254 prostate sides; the mean predicted rate was also 30%. The discriminatory value of the model was good, with an AUC of 80.4% (interquartile range 78.4–82.3%). The predicted probabilities matched the observed probabilities well (intercept −0.02, slope 1.053). There was slight underestimation of the observed probabilities from 70% upwards. In conclusion, an easy-to-use nomogram for side-specific EPE at RARP was externally validated and can be applied to virtually all PCa patients. PATIENT SUMMARY: A prediction model used to decide whether to spare the neurovascular bundles during removal of the prostate can be applied to virtually all prostate cancer patients.
format Online
Article
Text
id pubmed-8883192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88831922022-03-02 External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy Veerman, Hans Heymans, Martijn W. van der Poel, Henk G. Eur Urol Open Sci Brief Correspondence The aim of this study was to externally validate a nomogram for side-specific extraprostatic extension (EPE) of prostate cancer (PCa) at robot-assisted radical prostatectomy (RARP). A prospectively maintained cohort of 1170 consecutive patients with PCa who underwent RARP at two high-volume RARP centres between 2018 and 2021 was retrospectively evaluated. Biopsies and magnetic resonance imaging (MRI) scans were centrally reviewed. The side-specific probability of EPE was calculated for each prostate side using prostate-specific antigen density, ipsilateral highest biopsy Gleason score, and ipsilateral MRI tumour stage. Model discrimination and calibration were analysed using the area under the receiver operating characteristic curve (AUC), calibration in the large, and calibration curves. The rate of side-specific EPE was 30% among 2254 prostate sides; the mean predicted rate was also 30%. The discriminatory value of the model was good, with an AUC of 80.4% (interquartile range 78.4–82.3%). The predicted probabilities matched the observed probabilities well (intercept −0.02, slope 1.053). There was slight underestimation of the observed probabilities from 70% upwards. In conclusion, an easy-to-use nomogram for side-specific EPE at RARP was externally validated and can be applied to virtually all PCa patients. PATIENT SUMMARY: A prediction model used to decide whether to spare the neurovascular bundles during removal of the prostate can be applied to virtually all prostate cancer patients. Elsevier 2022-02-02 /pmc/articles/PMC8883192/ /pubmed/35243390 http://dx.doi.org/10.1016/j.euros.2021.12.010 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Correspondence
Veerman, Hans
Heymans, Martijn W.
van der Poel, Henk G.
External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title_full External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title_fullStr External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title_full_unstemmed External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title_short External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
title_sort external validation of a prediction model for side-specific extraprostatic extension of prostate cancer at robot-assisted radical prostatectomy
topic Brief Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883192/
https://www.ncbi.nlm.nih.gov/pubmed/35243390
http://dx.doi.org/10.1016/j.euros.2021.12.010
work_keys_str_mv AT veermanhans externalvalidationofapredictionmodelforsidespecificextraprostaticextensionofprostatecanceratrobotassistedradicalprostatectomy
AT heymansmartijnw externalvalidationofapredictionmodelforsidespecificextraprostaticextensionofprostatecanceratrobotassistedradicalprostatectomy
AT vanderpoelhenkg externalvalidationofapredictionmodelforsidespecificextraprostaticextensionofprostatecanceratrobotassistedradicalprostatectomy